Clinical Study

Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases

Kuang Pan,1 Lingna Deng,2 Peiying Chen,1 Qingxia Peng,1 Jingrui Pan,1 Yanfeng Wu,3 and Yidong Wang1,4,5

1Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
2Scientific Research Centre and Department of Orthopaedics, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China
3Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
4Guangdong Province Key Laboratory of Brain Function and Disease, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China
5Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China

Correspondence should be addressed to Yanfeng Wu; wuyf@mail.sysu.edu.cn and Yidong Wang; wydys@126.com

Received 19 January 2019; Revised 10 March 2019; Accepted 2 April 2019; Published 25 July 2019

Academic Editor: Marcin Majka

Copyright © 2019 Kuang Pan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mesenchymal stromal cells (MSCs) have become the most commonly used adult stem cells in regenerative medicine. Preclinical studies have shown that MSCs-based therapy is a potential new treatment approach for neurological diseases. Intrathecal injection has unique feature which allows stem cells to directly migrate to the lesion site in patients with central nervous system (CNS) diseases. In this study, we evaluate the safety and feasibility of intrathecal allogeneic bone marrow-derived MSCs (BM-MSCs) in patients with neurological diseases. This open-label clinical study included 37 patients (14 diseases). Eligible patients underwent a baseline assessment and were intrathecally injected with allogeneic BM-MSCs (1 × 10^6 cells/kg, 4 consecutive treatments at 1-week intervals). After four infusions, the patients were followed up for at least 6 months. Adverse events, cerebrospinal fluid (CSF) test results, clinical symptoms, physical examination, and haematological and imaging examinations were used to assess the safety and feasibility of the treatment. Also, we performed a systematic review of the safety of all types of intrathecal stem cells and compared our result to previous studies. In our study, the highest adverse event was a slight ache at the injection site (4.11%), followed by fever (3.42%) and mild headache (2.05%). No severe adverse events were reported. After the intrathecal injections, the white blood cell (WBC) counts in the CSF increased in 30 patients and the protein concentration in the CSF exceeded the normal range in 26 patients, while other CSF indicators remained normal. Moreover, these patients had no suspected manifestations of CNS infection. Haematological and imaging examinations showed no abnormal changes after BM-MSCs infusion. Compared with previous studies, the incidence of adverse events was nearly consistent or even lower for headache, fever, nausea, and neck pain. In conclusion, repeated intrathecal allogeneic BM-MSCs are safe, feasible, and promising for the treatment of patients with neurological diseases.

1. Introduction

Currently, many neurological diseases are difficult to cure and may even gradually progress after treatment. Patients with refractory neurological diseases suffer from paralysis, loss of social function, and difficulty of living, which places a heavy burden on society and their families. The promotion of neurological functional recovery and delaying disease progression are the main treatment goals in refractory neurological diseases [1]. Stem cells have the potential for self-renewal
and multidirectional differentiation and are therefore ideal cell sources for nerve regeneration and repair [2]. In recent years, stem cells have become a very promising new direction for the treatment of refractory neurological diseases [3].

Mesenchymal stromal cells (MSCs) derived from multiple tissues such as bone marrow (BM), umbilical cord, peripheral blood, and adipose tissue and under standard culture conditions can differentiate into a variety of cells including bone, fat, cartilage, neurons, hepatocytes, and cardiomyocytes [4]. MSCs are a group of cells which must express CD105, CD73, and CD90 and lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR surface molecules [5]. According to current criteria, the isolation of MSCs produces heterogeneous, nonclonal cultures of stromal cells containing stem cells with different multipotential properties, committed progenitors, and differentiated cells [3]. Due to their unique features, MSCs have become the most commonly used adult stem cells in regenerative medicine [3]. Because they have lower immune suppression properties and immunogenicity compared with other cell types, the implantation of allogeneic MSCs may be more feasible and appropriate in the treatment of human diseases [6]. In particular, the use of allogeneic MSCs transplantation in patients with ischaemic stroke is more suitable than autologous MSCs transplantation [7]. In terms of the routine of transplantation, there are four principal methods to introduce cells into the body in patients with neurological diseases: intracerebral or intraspinal injection, intrathecal injection, intra-arterial injection, and intravenous injection [8–10]. In patients with central nervous system (CNS) diseases, intrathecal injection allows for higher concentrations of stem cells to migrate to the lesion site compared with intra-arterial or intravenous injection. Moreover, intrathecal injection is safer than either intracerebral injection or intraspinal injection. Therefore, MSCs transplantation via intrathecal injection may be the best route for stem cell therapy in patients with neurological disorders [7].

In this clinical study, we aimed to assess the safety and feasibility of repeated intrathecal allogeneic bone marrow-derived MSCs (BM-MSCs) injections in patients with CNS diseases. These diseases, including severe stroke, are primarily caused by the degeneration and/or death of neurons in the brain and/or spinal cord and currently lack effective treatments [11–13]. We described the adverse events, cerebrospinal fluid (CSF) test results, clinical symptoms, and haematological and imaging examination results in patients enrolled in our study and compared our results with those achieved in previous related studies reported in the literature. This information is provided for follow-up clinical trials.

2. Materials and Methods

2.1. Patient Enrolment. We performed an open-label clinical study in the Department of Neurology, Sun Yat-sen Memorial Hospital. The study was approved by the Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University (Guangzhou, China). Part of the study has been registered in the Chinese Clinical Trial Registry (registration number: ChiCTR-INR-16008908). The inclusion criteria used for the study were as follows: (1) a neurological disease diagnosis that met the diagnostic criteria of Goldman’s Cecil Medicine 24th edition [13] and (2) willingness of the patient and his/her family to sign an informed consent form and good compliance with examination, treatment, and follow-up. The exclusion criteria used for the study were as follows: (1) inflammatory or autoimmune diseases within half a year before recruitment (such as infectious diseases, systemic lupus erythematosus, rheumatoid or rheumatic disease, or thyroid disease); (2) glucocorticoid, immunosuppressant, or gamma globulin use within 15 days; (3) nosocomial infection; (4) a severe medical condition, such as cerebral hernia, status epilepticus, single or multiple organ failure, or unstable vital signs; (5) acute myocardial infarction; (6) hematologic disorders; (7) tumour; (8) pregnant or lactating women; (9) allergy to local anaesthetic; and (10) current participation in another clinical trial or participation in another clinical trial within 30 days.

2.2. Preparation of Allogeneic BM-MSCs. All procedures were performed at the Centre for Biotherapy (GMP certificate number: 2015A10413), Sun Yat-sen Memorial Hospital, Sun Yat-sen University (Guangzhou, China). All healthy donors were informed of the relevant scientific contributions of the study, the possible risks and complications of treatment, and the corresponding prevention and treatment measures for bone marrow aspirations. All participants then signed the informed consent form. The protocols for isolation, expansion, passaging, and storing of BM-MSCs were performed as described in our previous works [14, 15]. The procedures for preparing allogeneic BM-MSCs were provided in the Supplementary Materials (available here). After identifying MSCs immunophenotyping markers by flow cytometry, passages three to five were used for the clinical study.

2.3. Cell Therapy Protocol. Each patient received 4 consecutive allogeneic BM-MSCs treatments at 1-week intervals. Allogeneic BM-MSCs (1 × 10⁶ cells/kg body weight) in 10 ml normal saline were slowly infused intrathecally over approximately 10 min after the injection of a mixture containing 2 mg (0.4 ml) of dexamethasone and 0.6 ml of normal saline (to prevent aseptic chemical meningitis). After the infusion of the BM-MSCs, 2 ml of normal saline was injected to flush the syringe and spread the BM-MSCs.

2.4. Clinical and Laboratory Assessment. Basic information related to the patients was collected before BM-MSCs transplantation. Adverse events were monitored during the course of cell therapy and throughout follow-up. Routine, biochemistry and aetiological tests of CSF were performed at each injection. Clinical symptoms and physical examinations were performed at each injection and during follow-up. Haematological indicators (including blood cell counts and liver and renal function) were examined before and during BM-MSCs transplantation in the first and the third month of follow-up. Chest X-ray, electrocardiogram, and magnetic resonance image (MRI) of the brain and spinal cord were checked before cell transplantation and in the twelfth month.
after transplantation. After four infusions, the patients were followed up for at least 6 months.

2.5. Review of the Literature. To increase our understanding of the safety of intrathecal injection of stem cells, we systematically reviewed the safety of relevant treatments in the literature. Our review included all types of stem cells administered via intrathecal injection in humans, and we compared the adverse events, CSF examinations, haematological indicators, and MRI results between these studies and our own study. We searched PubMed for all clinical trial articles published in English using the following search string: (“Injections, Spinal”[Mesh] OR “Spinal Puncture”[Mesh] OR “Subarachnoid Space”[Mesh]) AND (“Stem Cells”[Mesh] OR “Mesenchymal Stromal Cells”[Mesh]). We reviewed the bibliographies of retrieved articles. In the literature, stem cells must be injected into the subarachnoid space. Only reports with available clinical and biological data and outcomes were included. Intraspinal, intramedullary, and intracerebral injections were excluded from this review. Intrathecal injection associated with tumour treatment was also excluded. The relevant data about adverse events, CSF examinations, haematological indicators, and MRI results were collected to assess and compare the evaluations of the safety of intrathecal stem cells presented in previous studies with the data obtained in our study. In the summary of adverse events, we described the frequency of occurrences in terms of person-time to more accurately collect frequency data.

2.6. Data Analysis. The data are presented as the means ± SD or medians (range) for continuous variables and as a number (%) for qualitative variables. In the analysis of outcomes, ANOVA with Dunnet’s multiple comparisons, Kruskal-Wallis tests, and chi-square tests were used where appropriate. All statistical tests were two tailed, and statistical significance was established at P < 0.05. All data were statistically analysed using SPSS 22.0 software (SPSS, Armonk, NY, USA), and all images were produced using GraphPad 7 software (GraphPad, San Diego, CA, USA).

3. Results

3.1. Baseline Characteristics of Patients in Our Study. From Dec. 2014 to Mar. 2018, a total of 14 diseases and 37 patients were evaluated (Table 1), including 12 cases of cerebral infarction, 5 cases of motor neuron disease, 4 cases of spinal cord injury, 3 cases of myelitis, 2 cases of spinocerebellar ataxia, 2 cases of multiple system atrophy, 2 cases of Alzheimer’s disease, 1 case of acute disseminated encephalomyelitis, 1 case of encephalopathy syndrome, 1 case of hereditary spastic paraplegia, 1 case of intracerebral haemorrhage, 1 case of multiple sclerosis, 1 case of traumatic brain injury, and 1 case of thomboplegia.

The median age of the patients was 53 years old (range 18-75), and the median course of the diseases from the first injection was 8 months (range 0.4-120). In all, 25 men and 12 women were included. The median follow-up was 23 months (range 6-42).

3.2. Adverse Events in Our Study. The rate of mortality associated with BM-MSCs therapy during transplantation and follow-up was 0, although the following two patients died during the follow-up period for other causes: patient MND-022, who was a 75-year-old woman who died of respiratory failure due to an upper respiratory tract infection in the 11th month after BM-MSCs therapy, and patient MND-025, who was a 65-year-old man who died at home in the 30th month after therapy because of pneumonia. After a detailed inquiry, we concluded that these two deaths were not related to BM-MSCs therapy. No other severe adverse events, such as convulsions, condition aggravation or new neurological symptoms, transplantation, or tumourigenesis were discovered during the follow-up period in our study.

Six types of adverse events were observed in this study: headache, dizziness, fever, nausea, pain at the puncture site, and neck pain (Table 2). ADEM-003 had a fever after the first and second intrathecal injections, with both fevers occurring approximately 40 hours after injection. The first fever reached 37.9°C, and the second fever reached 38.2°C. After physical cooling and rehydration, the patient’s body temperature dropped to normal. IS-015 had a fever on the day of the second intrathecal injection that reached a temperature of 40°C. The patient’s body temperature returned to normal 3 h after oral administration of “Loxoprofen sodium tablets 60 mg”, and the fever did not recur. Patient SCA-030 felt chilly at 3 hours and had a fever at 18 hours after the first intrathecal injection. Her body temperature reached 39.2°C, and she was given a “1 ml diclofenac sodium” injection. After the injection, her body temperature returned to normal, and the fever did not recur. SCI-035 had a fever that reached 38.5°C at 12 hours after the first intrathecal injection; the fever was accompanied by diarrhoea, which was considered acute gastroenteritis. After receiving antibiotics, the fever did not recur. HSP-005 appeared to have pain in the forehead starting from 2 hours after the 4th intrathecal injection. The headache was aggravated when sitting and walking. At that time, low intracranial pressure was taken into consideration. This symptom gradually improved within 3-6 days after intensified intravenous fluid injection. MND-025 had moderate headache, nausea, no fever, no jet vomiting, no neck pain, and no signs of meningeal irritation on the day after the first and second intrathecal injections, and the patient’s symptoms were relieved after rest. After 2 intrathecal injections, he gave up on stem cell therapy. AD-002 had mild neck pain beginning with the first intrathecal injection that lasted for approximately six months after the fourth injection. This pain was tolerable, and the patient was not given specific therapy. Other adverse effects included puncture site/lower back pain (6 person-time) and mild dizziness (2 person-time), both of which recovered on their own after lasting approximately 1-2 days.

3.3. CSF Examination in Our Study. The following routine biochemical examinations (Table 3) were performed: white blood cell (WBC) and total karyocyte counts, which were significantly higher in the treated patients (Figures 1(a) and 1(b)). Only 3 patients had WBC counts slightly higher than normal at baseline. After stem cell therapy, the WBC count
increased in 30 patients, while seven patients maintained a normal WBC count. Changes in the total karyocyte counts were generally consistent with those observed for leukocytes. Glucose decreased, and the difference was statistically significant at the third and fourth examinations (Figure 1(c)), although the findings remained in the normal range. No significant changes in the chloride, protein, and lactate dehydrogenase (LDH) levels were observed (Figures 1(d)–1(f)). Before treatment, the protein concentrations exceeded the normal range (0.15–0.45 g/l) in 19 patients and were in the normal range in the other patients. After the intrathecal injections, the protein concentration exceeded the normal range in 26 patients, with the highest being 1.48 g/l. All patients had normal levels of chloride and LDH before and after transplantation. SCI-034 was a male patient with a spinal cord injury and high paraplegia. When the first and second lumbar punctures were performed, almost no CSF was available for collection. At the third and fourth lumbar

| Case number | Type of disease | Age (years) | Gender | Onset time (months) | Intrathecal frequency (times) | Follow-up time (months) |
|-------------|----------------|-------------|--------|---------------------|-------------------------------|-------------------------|
| AD-001      | AD             | 69          | F      | 120                 | 4                             | 12                      |
| AD-002      | AD             | 54          | M      | 36                  | 4                             | 9                       |
| ADEM-003    | ADEM           | 38          | F      | 3                   | 4                             | 6                       |
| ES-004      | ES             | 24          | F      | 54                  | 4                             | 6                       |
| HSP-005     | HSP            | 40          | M      | 120                 | 4                             | 12                      |
| ICH-006     | ICH            | 19          | M      | 9                   | 4                             | 23                      |
| IS-007      | IS             | 52          | F      | 3                   | 4                             | 42                      |
| IS-008      | IS             | 44          | M      | 36                  | 4                             | 39                      |
| IS-009      | IS             | 72          | M      | 0.8                 | 4                             | 38                      |
| IS-010      | IS             | 73          | F      | 1.5                 | 4                             | 37                      |
| IS-011      | IS             | 44          | F      | 2                   | 4                             | 12                      |
| IS-012      | IS             | 66          | M      | 1                   | 4                             | 37                      |
| IS-013      | IS             | 36          | M      | 8                   | 4                             | 12                      |
| IS-014      | IS             | 62          | M      | 0.8                 | 4                             | 12                      |
| IS-015      | IS             | 64          | M      | 1                   | 4                             | 29                      |
| IS-016      | IS             | 53          | M      | 1                   | 4                             | 26                      |
| IS-017      | IS             | 55          | M      | 1                   | 4                             | 25                      |
| IS-018      | IS             | 70          | F      | 0.4                 | 4                             | 9                       |
| ML-019      | ML             | 20          | M      | 1                   | 4                             | 24                      |
| ML-020      | ML             | 31          | M      | 1.5                 | 4                             | 12                      |
| ML-021      | ML             | 18          | M      | 6                   | 4                             | 25                      |
| MND-022     | FAS            | 75          | F      | 24                  | 4                             | 11                      |
| MND-023     | ALS            | 42          | M      | 24                  | 4                             | 12                      |
| MND-024     | SMA            | 58          | M      | 48                  | 4                             | 35                      |
| MND-025     | PBP            | 64          | M      | 12                  | 2                             | 30                      |
| MND-026     | ALS            | 70          | M      | 24                  | 4                             | 12                      |
| MS-027      | MS             | 58          | F      | 48                  | 4                             | 26                      |
| MSA-028     | MSA            | 60          | M      | 12                  | 4                             | 37                      |
| MSA-029     | MSA            | 53          | F      | 19                  | 4                             | 12                      |
| SCA-030     | SCA            | 55          | F      | 12                  | 4                             | 39                      |
| SCA-031     | SCA            | 57          | F      | 60                  | 4                             | 25                      |
| SCI-032     | SCI            | 25          | M      | 1                   | 4                             | 38                      |
| SCI-033     | SCI            | 53          | M      | 2                   | 4                             | 37                      |
| SCI-034     | SCI            | 61          | M      | 12                  | 4                             | 18                      |
| SCI-035     | SCI            | 30          | M      | 6                   | 4                             | 8                       |
| TBI-036     | PTBS           | 30          | M      | 36                  | 4                             | 18                      |
| TP-037      | TP             | 33          | M      | 2                   | 4                             | 9                       |

Abbreviations: AD, Alzheimer’s disease; ADEM, acute disseminated encephalomyelitis; ALS, amyotrophic lateral sclerosis; ES, encephalopathy syndrome; FAS, flail arm syndrome; HSP, hereditary spastic paraplegia; ICH, intracerebral haemorrhage; IS, ischaemia stroke; ML, myelitis; MND, motor neuron disease; MS, multiple sclerosis; MSA, multiple system atrophy; PBP, progressive bulbar paralysis; SCA, spinocerebellar ataxia; SCI, spinal cord injury; SMA, progressive spinal muscular atrophy; TBI, traumatic brain injury; TP, thermoplegia; M, male; F, female.
punctures, his CSF was collected for examination. Therefore, he completed only two CSF examinations.

Regarding leukocytosis, we removed patients with erythrocytosis from the analysis because these patients had puncture damage at that time, which influenced the judgement of the CSF results. The remaining 21 patients (35 person-time) had leukocytosis. Among these patients, 8 (AD-001, HSP-005, ICH-006, IS-013, ML-021, MSA-028, SCA-030, and SCA-031) had a high WBC count (above \(10^6/\text{ml}\)) (12 person-time) but a normal CSF biochemistry examination. HSP-005 appeared to have pain in the frontal area at the intrathecal injection site as described above. Fourteen patients (IS-007, IS-008, IS-009, IS-011, IS-014, IS-015, IS-017, ML-021, MND-022, MND-023, MND-025, MSA-029, SCI-032, and SCI-033) presented elevated WBC counts and protein levels (23 person-time). With the exception of IS-015, who had a fever after the second intrathecal injection, and MND-025, who had moderate headache and nausea after the second intrathecal injection, the remaining 12 patients had no suspected manifestations of CNS infection, such as headache, fever, or signs of meningeal irritation, during the treatment period and within the follow-up period. Moreover, the levels of glucose and chloride in the CSF were normal in all of these patients.

Every aetiological examination performed in the CSF of all patients was normal. Examinations for Cryptococcus were negative, and Mycobacterium tuberculosis was quantified at a level below \(1.0 \times 10^3\) copies/ml.

3.4. Haematological and Imaging Examinations Performed in Our Study. In our study, the haematological examination, chest X-ray, and electrocardiogram results showed no abnormal changes after BM-MSCs infusion. Twenty-two of the 30 patients with at least 12 months of follow-up underwent an MRI examination 12 months after stem cell therapy. The results showed no neoplasms within the cranial cavity and spinal canal.

3.5. Adverse Events in Intrathecal Autologous MSCs Clinical Studies in the Literature. Intrathecal autologous MSCs transplantations have been reported in humans (Table 4) primarily for amyotrophic lateral sclerosis [16–22], followed by multiple sclerosis [16, 23–26] and spinal cord injury [27–32]. In addition, this approach has been reported in traumatic brain injury [33], epilepsy [34], and cerebral palsy [35]. Three types of autologous MSCs have been included in these studies: BM-MSCs, peripheral blood MSCs, and adipose-derived MSCs. A combination of intrathecal and intravenous injections was also included for analysis. All dose statistics were divided into two injection modes: one mode used in eight studies was based on patient body weight, and the doses fluctuated between \(0.1 \times 10^6/\text{kg}\) and \(10 \times 10^6/\text{kg}\) with a median of \(1 \times 10^6/\text{kg}\); the other mode was based on the use of a constant dose for each injection related to the preparation of the stem cells, and the doses fluctuated between \(0.7 \times 10^6\) and \(100 \times 10^6\) with a median of \(30 \times 10^6\). The frequency of injection was also very variable, with some studies performing the injection once, and most studies performing 2-3 injections at intervals ranging from 5 days to one month. The follow-up periods ranged from 14 days to 826 days. A total of 518 patients (1028 person-time) were included in the evaluated intrathecal autologous MSCs clinical studies. In previous studies, the most common adverse event was fever, which occurred in 7.88% (81/1028) of patients after treatment and was self-relieved or relieved after taking a drug. The next most common adverse event was pain at the injection site and back pain, which had an incidence rate of 7.30% (75/1028) and was related to the puncture operation. The occurrence of headache also attracted our attention because it occurred at a rate of 7.10% (73/1028) and might be related to changes in intracranial pressure. This symptom was alleviated by increasing hydration or was in some cases self-relieved. In addition, the proportions of patients with nausea and neck pain were 0.97% (10/1028) and 0.19% (2/1028), respectively. Other adverse events included adverse events in the motion system (including spasticity (5, 0.49%), difficulty walking/standing (4, 0.39%), weakness (3, 0.29%), rigidity (2, 0.19%), jerky movement (2, 0.19%), and neck stiffness (2, 0.19%)), adverse events in the sensory system (including leg and neuropathic pain (63, 6.13%) and tingling sensation (2, 0.19%)), and other events (including aseptic meningitis (49, 4.77%), vomiting (10, 0.97%), sweating (4, 0.39%), transient hypertension (4, 0.39%), urinary tract infection (4, 0.39%), bruising (3, 0.29%), dyspnoea (2, 0.19%), leukocytosis (2, 0.19%), confusion (1, 0.10%), syncope (1, 0.10%), nasophaangealitis (1, 0.10%), and bronchitis (1, 0.10%)). Transient encephalopathy with seizures a few days after cell injection was reported in only one case.

### Table 2: Adverse events for intrathecal injection of allogeneic MSCs.

| Adverse effects                  | AD  | ADEM | ES  | HSP | ICH | IS  | ML  | MND | MS  | MSA | SCA | SCI | TBI | TP | Total |
|---------------------------------|-----|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|
| (no. of patients)               | N=2 | N=1  | N=1 | N=1 | N=12| N=3 | N=5 | N=1 | N=2 | N=2 | N=2 | N=4 | N=1 | N=1 | N=37  |
| Headache                        | 0   | 0    | 1   | 0   | 0   | 0   | 0   | 2   | 0   | 0   | 0   | 0   | 0   | 0   | 3     |
| Dizziness                       | 0   | 0    | 0   | 0   | 0   | 1   | 1   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 2     |
| Fever                           | 0   | 2    | 0   | 0   | 0   | 1   | 0   | 0   | 0   | 0   | 1   | 1   | 0   | 0   | 5     |
| Nausea                          | 0   | 0    | 0   | 0   | 0   | 0   | 2   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 2     |
| Pain at puncture site           | 0   | 0    | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 6     |
| Neck pain                       | 1   | 0    | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 1     |

Abbreviations: AD, Alzheimer’s disease; ADEM, acute disseminated encephalomyelitis; ES, encephalopathy syndrome; HSP, hereditary spastic paraplegia; ICH, intracerebral haemorrhage; IS, ischaemia stroke; ML, myelitis; MND, motor neuron disease; MS, multiple sclerosis; MSA, multiple system atrophy; SCA, spinocerebellar ataxia; SCI, spinal cord injury; TBI, traumatic brain injury; TP, thermoplegia.
In that case, the patient used intravenous valproate and recovered without significant sequelae. No other serious adverse events were reported.

The adverse events observed in our study and in previous studies of intrathecal autologous MSCs were compared (Table 5). The frequency of headache was significantly lower in our trial ($P < 0.05$), whereas the frequency of dizziness was higher in our trial because no dizziness was reported in previous autologous MSCs studies. No differences in fever, nausea, pain at the puncture site, and neck pain were observed between our study and previous studies.

### 3.6. Adverse Events in Intrathecal Allogeneic MSCs Clinical Studies in the Literature

Only four articles about intrathecal allogeneic MSCs clinical studies could be retrieved (Table 6). All MSCs in these studies were umbilical cord derived [36–39]. The infusion dose fluctuated between $1 \times 10^6$ and $20 \times 10^6$, and the median was $1 \times 10^7$. The frequencies of injection were

### Table 3: Number of WBCs and levels of protein in the CSF in our study.

| Patient | WBC ($\times 10^6$/l) | Protein (g/l) |
|---------|------------------------|--------------|
|         | First | Second | Third | Fourth | First | Second | Third | Fourth |
| AD-001  | 0.3   | 8      | 18    | 12     | 0.24  | 0.28   | 0.27  | 0.26   |
| AD-002  | 2     | 24     | 19    | 9      | 0.23  | 0.30   | 0.35  | 0.29   |
| ADEM-003| 0     | 1      | 1     | 0      | 0.54  | 0.58   | 0.69  | 1.10   |
| ES-004  | 2     | 12     | 15    | 18     | 0.93  | 0.87   | 1.25  | 0.97   |
| HSP-005 | 1     | 2      | 4     | 78     | 0.21  | 0.22   | 0.18  | 0.29   |
| ICH-006 | 3     | 9      | 41    | 122    | 0.25  | 0.25   | 0.42  | 0.46   |
| IS-007  | 6     | 6      | 20    | 26     | 0.66  | 0.64   | 0.81  | 0.62   |
| IS-008  | 5     | 15     | 124   | 230    | 0.52  | 0.58   | 0.87  | 0.99   |
| IS-009  | 1     | 2      | 12    | 3      | 0.46  | 0.58   | 0.53  | 0.51   |
| IS-010  | 1     | 6      | 8     | 3      | 0.59  | 0.63   | 0.56  | 0.41   |
| IS-011  | 3     | 11     | 9     | 10     | 0.54  | 0.50   | 0.49  | 0.53   |
| IS-012  | 4     | 6      | 1     | 5      | 0.75  | 0.75   | 0.79  | 0.81   |
| IS-013  | 2     | 35     | 36    | 25     | 0.26  | 0.35   | 0.30  | 0.31   |
| IS-014  | 9     | 9      | 9     | 12     | 0.57  | 0.52   | 0.59  | 0.66   |
| IS-015  | 2     | 13     | 33    | 45     | 0.55  | 0.70   | 1.26  | 0.85   |
| IS-016  | 1     | 6      | 8     | 3      | 0.59  | 0.63   | 0.56  | 0.41   |
| IS-017  | 3     | 7      | 6     | 11     | 0.69  | 1.04   | 0.40  | 1.85   |
| IS-018  | 5     | 10     | 7     | 7      | 0.49  | 0.56   | 0.63  | 1.48   |
| ML-019  | 2     | 1      | 2     | /      | 0.52  | 0.35   | 0.26  | /      |
| ML-020  | 1     | 2      | 2     | 2      | 0.25  | 0.31   | 0.43  | 0.49   |
| ML-021  | 12    | 16     | 19    | 72     | 0.25  | 0.29   | 0.29  | 0.58   |
| MND-022 | 1     | 13     | 11    | 7      | 0.48  | 0.50   | 0.44  | 0.44   |
| MND-023 | 1     | 12     | 11    | 18     | 0.60  | 0.76   | 0.54  | 0.46   |
| MND-024 | 0     | 8      | 3     | 128    | 0.40  | 0.29   | 0.41  | 0.49   |
| MND-025 | 2     | 15     | /     | /      | 0.35  | 0.48   | /     | /      |
| MND-026 | 2     | 10     | 5     | 2      | 0.69  | 0.85   | 0.75  | 0.71   |
| MS-027  | 2     | 2      | 4     | 0      | 0.31  | 0.34   | 0.37  | 0.35   |
| MSA-028 | 2     | 4      | 5     | 18     | 0.26  | 0.28   | 0.25  | 0.34   |
| MSA-029 | 1     | 112    | 206   | 155    | 0.24  | 0.55   | 0.42  | 0.50   |
| SCA-030 | 2     | 13     | 17    | 23     | 0.26  | 0.22   | 0.29  | 0.31   |
| SCA-031 | 3     | 19     | 23    | 81     | 0.21  | 0.23   | 0.24  | 0.26   |
| SCI-032 | 6     | 26     | 49    | 49     | 0.64  | 0.59   | 0.59  | 0.99   |
| SCI-033 | 15    | 280    | 119   | 112    | 0.80  | 1.19   | 0.98  | 0.95   |
| SCI-034 | /     | /      | 0     | 16.4   | /     | /      | 0.55  | 0.49   |
| SCI-035 | 4     | 3      | 4     | 11     | 0.34  | 0.33   | 0.32  | 0.20   |
| TBI-036 | 2.6   | 7      | 21    | 34.3   | 0.24  | 0.22   | 0.28  | 0.23   |
| TP-037  | 3     | 6      | 13    | 8      | 0.90  | 0.77   | 0.74  | 0.94   |

Abbreviations: AD, Alzheimer’s disease; ADEM, acute disseminated encephalomyelitis; ES, encephalopathy syndrome; HSP, hereditary spastic paraplegia; ICH, intracerebral haemorrhage; IS, ischaemia stroke; ML, myelitis; MND, motor neuron disease; MS, multiple sclerosis; MSA, multiple system atrophy; PBP, progressive bulbar paralysis; SCA, spinocerebellar ataxia; SCI, spinal cord injury; TBI, traumatic brain injury; TP, thermoplegia.
The intervals ranged from 5 to 7 days. The follow-up periods were 3 to 36 months. A total of 67 patients (258 person-time) participated in these studies. The top three adverse events were headache in 2.71% (7/258), dizziness in 2.33% (6/258), and fever in 1.16% (3/258) of the cases.

The studies of intrathecal allogeneic MSCs only showed a lower ratio of pain at the puncture site, and this difference was significant when comparing with our results (Table 7). No differences in the other adverse events were observed between our study and previous studies.

3.7. Adverse Events in Intrathecal Non-MSCs Stem Cells in Clinical Studies in the Literature. To know about whether intrathecal MSCs were safer than intrathecal non-MSCs stem cells, we included clinical studies of intrathecal non-MSCs stem cells described in the literature and made a comparison. These non-MSCs stem cells included autologous bone marrow haematopoietic stem cells [40], autologous bone marrow mononuclear cells [35, 41–44], allogeneic cord blood mononuclear cells [38, 45], autologous bone marrow progenitor cells [46], autologous bone marrow aspirate concentrate [47], and autologous bone marrow stem cells [48]. Mononuclear cells and bone marrow aspirate concentrates contain some stem cells. Progenitor cells are a subpopulation of BM-derived haematopoietic stem cells. Therefore, these three types of cells were included in the analysis (Table 8).

Except for injection doses determined according to the unit weight, the doses in the other studies fluctuated between
| Authors/country | Diagnosis | No. of treated patients | Stem cell type | Transplant type | Dose per injection | Injection frequency | Follow-up | Adverse events (person-time) |
|----------------|-----------|-------------------------|----------------|----------------|-------------------|-------------------|-----------|-----------------------------|
| Bonab et al. [23]/Iran | MS | 10 | Auto-BM-MSCs | IT | $8.73 \times 10^6$ | 1 | 13–26 months | Slight headache (9); iatrogenic meningitis (2) |
| Pal et al. [27]/India | SCI | 30 | Auto-BM-MSCs | IT | $1 \times 10^6$/kg | 2–3, weekly | 12–24 months | None |
| Karussis et al. [16]/Israel | MS | 15 | Auto-BM-MSCs | IT+IV | $63.2 \times 10^6$; $54.7 \times 10^6$ | 1 | 25 months | Fever (21); headache (15); meningism (1); rigidity (2); leg pain (3); dyspnoea (1); confusion (1); neck pain (1); difficulty walking/standing (4) |
| Yamout et al. [24]/Lebanon | MS | 7 | Auto-BM-MSCs | IT | $(32-100) \times 10^6$ | 1 | 12 months | Seizures (1); cervical and lower back pain (3) |
| Kishk et al. [28]/Egypt | SCI | 44 | Auto-BM-MSCs | IT | $(5-10) \times 10^6$/kg | 6, monthly | 12 months | None |
| Hammadi et al. [25]/Iraq | MS | 50 | Auto-PB MSCs | IT | $2.7 \times 10^6$ | 1–8 (mean 2.14) | 12 months | Backache (45); meningism (45) |
| Bonab et al. [26]/Iran | MS | 25 | Auto-BM-MSCs | IT | $29.5 \times 10^6$ | 1 | 12 months | Fever (5); headache (2) |
| Karamouzian et al. [29]/Iran | SCI | 11 | Auto-BM-MSCs | IT | $(7-12) \times 10^5$ | 1 | 12–33 months | Pain (8) |
| Tian et al. [33]/China | TBI | 97 | Auto-BM-MSCs | IT | $5 \times 10^6$ | 1 | 2 weeks | Fever (11); myalgia (9); lower back pain (4); headache (4) |
| Kim et al. [17]/Korea | ALS | 37 | Auto-BM-MSCs | IT | $1 \times 10^6$/kg | 2, monthly | 6 months | Fever (4); administration site pain (3); headache (3) |
| Oh et al. [18]/Korea | ALS | 8 | Auto-BM-MSCs | IT | $1 \times 10^6$/kg | 2, at 26-day intervals | 12 months | Fever (11); administration site pain (3); headache (3) |
| Rushkevich et al. [19]/Belarus | ALS | 10 | Auto-BM-MSCs | IT+IV | $(5-9.7) \times 10^6$ | 1–2, at 5–7-month intervals | 12 months | Fever (1); headache (2) |
| Petrou et al. [20]/Israel | ALS | 26 | Auto-BM-MSCs | IT+IV | $(1-2) \times 10^6$/kg | 1 | 6 months | Headache (13); fever (11); back/leg pains (8); vomiting (3); neck stiffness (2); general weakness (1); bruising (1); spasticity (1) |
| Authors/country           | Diagnosis | No. of treated patients | Stem cell type | Transplant type | Dose per injection | Injection frequency | Follow-up | Adverse events (person-time)                                                                 |
|---------------------------|-----------|-------------------------|----------------|------------------|--------------------|---------------------|-----------|---------------------------------------------------------------------------------------------|
| Satti et al. [31]/Pakistan| SCI       | 9                       | Auto-BM-MSCs   | IT               | $(0.9-2.57) \times 10^6$/kg | 2–3, monthly        | 269–826 days | Headache (1); tingling sensation (2)                                                        |
| Hlebokazov et al. [34]/Belarus| EP     | 10                      | Auto-BM-MSCs   | IT+IV            | $1 \times 10^5$/kg       | 1                   | 12 months | Headache (1)                                                                                |
| Hur et al. [30]/Korea     | SCI       | 14                      | Auto-AD MSCs   | IT               | $3 \times 10^7$        | 3, monthly          | 8 months | Urinary tract infection (1); headache (2); nausea and vomiting (1)                          |
| Staff et al. [21]/USA     | ALS       | 27                      | Auto-AD MSCs   | IT               | $(1-10) \times 10^7$   | 1–2, monthly        | 4–108 weeks | Headache (3); back/leg pain (9)                                                             |
| Liu et al. [35]/China     | CP        | 33                      | Auto-BM-MSCs   | IT               | $1 \times 10^6$/kg      | 4, at 3–4-day intervals | 12 months | Fever (2); nausea, vomiting, and headache (4)                                               |
| Sykova et al. [22]/Czech  | ALS       | 26                      | Auto-BM-MSCs   | IT               | $(10.5-19.5) \times 10^6$ | 1                   | 18 months | Headache (7); hyperhidrosis (1); leukocytosis (2); Hypertension (1); local pain (1); leg pain (1); urinary tract infection (3); headache (4); hyperthermia (1); wound (1); infected pressure ulcer (1); arthralgia (1); syncope (1); pain in coccyx (1); neck pain (1); back pain (1); nasopharyngitis (1); bronchitis (1) |
| Vaquero et al. [32]/Spain | SCI       | 10                      | Auto-BM-MSCs   | IT               | $30 \times 10^6$       | 4, 3 months         | 12 months |                                                                                             |

Abbreviations: AD, adipose derived; ALS, amyotrophic lateral sclerosis; auto, autologous; BM, bone marrow; CP, cerebral palsy; EP, epilepsy; MS, multiple sclerosis; MSCs, mesenchymal stem cells; PB, peripheral blood; SCI, spinal cord injury; TBI, traumatic brain injury; IT, intrathecal; IV, intravenous.
and $5.387 \times 10^6$, with a median of $4 \times 10^7$. The frequency of injection was mostly once, and the most was 5 times. The interval ranged from 3 days to 1 month. The follow-up period was 1 to 24 months. These clinical studies included 604 patients (1241 person-time). The incidence of headache was the highest (8.94%, 111/1241), and it was followed by fever (8.78%, 109/1241). The rates of nausea and pain at the puncture site were 1.45% (18/1241) and 2.10% (26/1241), respectively. Other adverse events observed in intrathecal non-MSCs stem cells included events related to the motion system (including shivering (3, 0.24%) and spasm (2, 0.16%)) or the sensory system (including lower limb, muscle, and neuropathic pain (20, 1.61%) and tingling sensation (6, 5.48%)) and other events (including vomiting (20, 1.61%), lingual oedema (1, 0.08%), laryngeal stridor (1, 0.08%), and bronchoconstriction (1, 0.08%)). One serious adverse event was reported in a previous study [46]. A 9-year-old boy with a history of seizure stopped anticonvulsants 3 years before cell therapy, and seizures occurred once in the sixth month after cell therapy. The seizures were well controlled, and his examinations were normal.

Our results were significantly different from those reported in the previous literature of intrathecal non-MSCs stem cells with regard to headache, dizziness, and fever. The proportions of patients with headaches and fever were lower in our study than in previous studies. However, the rate of dizziness was slightly higher in our study (Table 9). This result is consistent with trials of autologous mesenchymal stem cells.

### Table 5: Comparison of adverse events between our study and previous clinical studies of intrathecal autologous MSCs.

| Adverse events (person-time) | Total (%) | Our study (%) | Literature review (%) | P |
|-----------------------------|-----------|---------------|-----------------------|---|
| Headache                    | 76 (6.47) | 3 (2.05)      | 73 (7.10)             | 0.032 |
| Dizziness                   | 2 (0.17)  | 2 (1.37)      | 0 (0.00)              | 0.015 |
| Fever                       | 86 (7.32) | 5 (3.42)      | 81 (7.88)             | 0.053 |
| Nausea                      | 12 (1.02) | 2 (1.37)      | 10 (0.97)             | 0.995 |
| Pain at puncture site       | 81 (6.90) | 6 (4.11)      | 75 (7.30)             | 0.155 |
| Neck pain                   | 3 (0.26)  | 1 (0.68)      | 2 (0.19)              | 0.824 |

### Table 6: Clinical studies of intrathecal allogeneic MSCs described in the literature.

| Authors/country | Diagnosis | No. of treated patients | Stem cell type | Transplant type | Dose per injection | Injection frequency | Follow-up | Adverse event (person-time) |
|-----------------|-----------|-------------------------|----------------|----------------|-------------------|---------------------|-----------|-----------------------------|
| Jin et al. [36]/China | SCA      | 16                      | UCMSCs         | IT+IV          | $2 \times 10^7$    | 3, weekly          | 12 months | Fever (1); dizziness (2); headache (2) |
| Lv et al. [38]/China   | Autism    | 9                       | UCMSCs         | IT+IV          | $(1-2) \times 10^6$ | 2, at 5–7-day intervals | 6 months | Fever (2)                   |
| Wang et al. [39]/China | TBI       | 20                      | UCMSCs         | IT             | $1 \times 10^7$    | 4, at 5–7 day intervals | 6 months | Dizziness (4); headache (4) Lumbago (1); headache (1) |
| Liu et al. [37]/China   | SCI       | 22                      | UCMSCs         | IT             | $1 \times 10^6$/kg | 4–12, weekly       | 3–36 months |                             |

Abbreviations: SCA, hereditary spinocerebellar ataxia; SCI, spinal cord injury; TBI, traumatic brain injury; UCMSCs, umbilical cord mesenchymal stem cells; IT, intrathecal; IV, intravenous.

### Table 7: Comparison of adverse events between our study and previous clinical studies of intrathecal allogeneic MSCs.

| Adverse events (person-time) | Total (%) | Our study (%) | Literature review (%) | P |
|-----------------------------|-----------|---------------|-----------------------|---|
| Headache                    | 10 (2.48) | 3 (2.05)      | 7 (2.71)              | 0.940 |
| Dizziness                   | 8 (1.98)  | 2 (1.37)      | 6 (2.33)              | 0.771 |
| Fever                       | 8 (1.98)  | 5 (3.42)      | 3 (1.16)              | 0.232 |
| Nausea                      | 2 (0.50)  | 2 (1.37)      | 0 (0.00)              | 0.130 |
| Pain at puncture site       | 7 (1.73)  | 6 (4.11)      | 1 (0.39)              | 0.018 |
| Neck pain                   | 1 (0.25)  | 1 (0.68)      | 0 (0.00)              | 0.361 |

1 $\times 10^6$ and 5387 $\times 10^6$, with a median of 4 $\times 10^7$. The frequency of injection was mostly once, and the most was 5 times. The interval ranged from 3 days to 1 month. The follow-up period was 1 to 24 months. These clinical studies included 604 patients (1241 person-time). The incidence of headache was the highest (8.94%, 111/1241), and it was followed by fever (8.78%, 109/1241). The rates of nausea and pain at the puncture site were 1.45% (18/1241) and 2.10% (26/1241), respectively. Other adverse events observed in intrathecal non-MSCs stem cells included events related to the motion system (including shivering (3, 0.24%) and spasm (2, 0.16%)) or the sensory system (including lower limb, muscle, and neuropathic pain (20, 1.61%) and tingling sensation (6, 5.48%)) and other events (including vomiting (20, 1.61%), lingual oedema (1, 0.08%), laryngeal stridor (1, 0.08%), and bronchoconstriction (1, 0.08%)). One serious adverse event was reported in a previous study [46]. A 9-year-old boy with a history of seizure stopped anticonvulsants 3 years before cell therapy, and seizures occurred once in the sixth month after cell therapy. The seizures were well controlled, and his examinations were normal.

Our results were significantly different from those reported in the previous literature of intrathecal non-MSCs stem cells with regard to headache, dizziness, and fever. The proportions of patients with headaches and fever were lower in our study than in previous studies. However, the rate of dizziness was slightly higher in our study (Table 9). This result is consistent with trials of autologous mesenchymal stem cells.

3.8. Comparison of Adverse Events among Clinical Studies of Intrathecal Autologous MSCs, Allogeneic MSCs, and Non-MSCs Stem Cells. We included our study in the analysis of allogeneic MSCs (Table 10). We found no significant difference in nausea and neck pain among these three groups, and the frequencies of all three were low. The proportion of patients with headaches and fever was lower in allogeneic MSCs than in autologous MSCs and other non-MSCs types.
| Authors/country | Diagnosis | No. of treated patients | Stem cell type | Transplant type | Dose per injection | Injection frequency | Follow-up | Adverse events (person-time) |
|----------------|-----------|-------------------------|----------------|----------------|------------------|--------------------|----------|-------------------------------|
| Callera and do Nascimento [40]/Brazil | SCI | 10 | Auto-BM HSCs | IT | $100 \times 10^6$ | 1 | 12 weeks | Uneventful |
| Kumar et al. [41]/India | SCI | 297 | Auto-BM MCs | IT | $(3.66-4.26) \times 10^8$ | 1 | 18.4–20.5 months | Fever (95); headache (67); tingling sensation (68); spasm (1); neuropathic sensory symptoms (17) |
| Yang et al. [45]/China | Degenerative conditions* | 114 | CBMCs | IT+IV | $(1-3) \times 10^7$ | 4-5, weekly | 4-5 weeks | Fever (95); headache (67); tingling sensation (68); spasm (1); neuropathic sensory symptoms (17) |
| Sharma et al. [43]/India | SCI | 38 | Auto-BM MCs | IT+1M | $1 \times 10^6$/kg | 1 | 6-24 months | Headache (12); nausea (7); backache (10); vomiting (5) |
| Saito et al. [42]/Japan | SCI | 5 | Auto-BM MCs | IT | $(3-5) \times 10^7$ | 1 | 6 months | None |
| Lv et al. [38]/China | Autism | 23 | CBMCs | IT+IV | $(1-2) \times 10^6$ | 2-3, at 5-7-day intervals | 6 months | Fever (95); headache (67); tingling sensation (68); spasm (1); neuropathic sensory symptoms (17) |
| Mancias-Guerra et al. [44]/Mexico | CP | 18 | Auto-BM MCs | IT+IV | $(4.38-53.87) \times 10^8$ | 1 | 6 months | Headache (5); nausea and vomiting (5); seizure (1); back pain (11) |
| Zali et al. [46]/Iran | CP | 12 | Auto-BM PCs | IT | $(6-15.6) \times 10^6$ | 1 | 6 months | None |
| Bansal et al. [47]/India | Autism | 10 | Auto-BM AC | IT | Not mentioned | 1 | 24 months | None |
| Bansal et al. [48]/India | SCI | 10 | Auto-BM SCs | IT | Not mentioned | 3, monthly | 12 months | Spastic contraction (1); calf muscle pain (1); bronchoconstriction (1) |
| Liu et al. [35]/China | CP | 34 | Auto-BM MCs | IT | $1 \times 10^6$/kg | 4, at 3–4-day intervals | 12 months | None |

Abbreviations: CP, cerebral palsy; MD, muscular dystrophy; SCI, spinal cord injury. *Included (no. of patients): paraplegia (42), ataxia (23), multiple sclerosis (19), amyotrophic lateral sclerosis (12), sequelae of cerebrovascular diseases (6), multiple system atrophy (4), motor neuron disease (2), cerebral palsy (1), nerve injury (brachial plexus) (1), traumatic brain injury sequelae (1), hypoxic-ischaemic encephalopathy sequelae (1), cervical spondylotic myelopathy (1), and optic nerve hypoplasia (1). Auto: autologous; AC: aspirate concentrate; BM: bone marrow; CBMCs: cord blood mononuclear cells; HSCs: haematopoietic stem cells; MCs: mononuclear cells; PCs: progenitor cells; SCs: stem cells; UCMSCs: umbilical cord mesenchymal stem cells.
We unexpectedly found that dizziness occurred only in intrathecal allogeneic MSCs, although its occurrence rate was low. Autologous MSCs trials had the highest proportion of patients with pain at the puncture site. Moreover, as outlined above, other adverse events were reported in the literature in studies exploring intrathecal autologous MSCs and non-MSCs stem cells.

3.9. Other Safety Indicators Described in Previous Studies. Only a small number of studies contained information about examinations of CSF, haematological indicators, and MRI results. We analysed the 33 relevant articles and found that one literature detailed the results of CSF examinations, two articles listed results for haematology, and 18 articles described MRI results. In the study of CSF [21], nuclear cells and protein levels increased, while glucose levels slightly decreased but remained in the normal range. The literature containing data for haematological indicators showed that there were no significant changes [38, 45]. There were 18 articles [20–24, 26–28, 30–32, 36, 39, 42–44, 46, 48] that included MRI results obtained during follow-up, and no tumourigenesis was reported.

4. Discussion

To our knowledge, this clinical study is the first report to be published in English that describes repeated intrathecal injection of allogeneic BM-MSCs for the treatment of neurological diseases. A total of 37 cases were observed that involved 14 diseases with a maximum follow-up period of 42 months. We found that performing four intrathecal injections of allogeneic BM-MSCs at $1 \times 10^6$ cells/kg body weight at an interval of one week was safe and produced no serious adverse events. In our study, adverse events, clinical symptoms, physical signs, CSF tests, and haematological and imaging examinations were monitored. Adverse events were found in 37 patients and included puncture site/lower back pain (6 person-time), fever (5 person-time), headache (3 person-time), mild dizziness (2 person-time), nausea (2 person-time), and neck pain (1 person-time). Pain at the puncture site was associated with injury resulting from lumbar puncture and operator skill, and dizziness may be associated with changes in the volume of CSF. When manifestations such as fever, headache, and neck pain are encountered, CNS infection must be excluded. The WBC counts and protein concentrations of CSF were evaluated in the patients with these symptoms (ADEM-003, HSP-005, IS-015, MND-025, and SCA-030) and were found to be outside normal levels. However, the levels of glucose, chlorine, and LDH in the CSF were normal, and there were no signs of meningeal irritation. Therefore, CNS infection could be excluded, and the symptoms may be attributable to aseptic meningitis or low intracranial pressure. The CSF results of two patients (AD-002 and SCI-035) suffering adverse events were always in the normal range, indicating that their symptoms may have been attributable to acute infusion-associated toxicity. Cases were observed in which WBC counts and/or protein levels in CSF increased without adverse events. The causes of these CSF abnormalities may have been an acute response by intraspinal tissues to the BM-MSCs.

Compared with past clinical studies, adverse events in our study occurred at a greater or lower frequency. The frequencies of fever and headache were lower in our study than in those exploring non-MSCs stem cells, and the frequencies of headache were lower in autologous MSCs trials. The frequencies of nausea and neck pain were the same in this trial as in other MSCs trials. The proportion of patients with

| Table 9: Comparison of adverse events between our study and previous studies of intrathecal non-MSCs stem cells. |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Adverse events (person-time) | Total (%) | Our study (%) | Literature review (%) |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| N = 1389 | N = 146 | N = 1241 |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Headache | 114 (8.21) | 3 (2.05) | 111 (8.94) |
| Dizziness | 2 (0.14) | 2 (1.37) | 0 (0.00) |
| Fever | 114 (8.21) | 5 (3.42) | 109 (8.78) |
| Nausea | 20 (1.44) | 2 (1.37) | 18 (1.45) |
| Pain at puncture site | 32 (2.30) | 6 (4.11) | 26 (2.10) |
| Neck pain | 1 (0.07) | 1 (0.68) | 0 (0.00) |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| P | 0.007 | 0.011 | 0.026 |

| Table 10: Comparison of adverse events among clinical studies of intrathecal autologous MSCs, allogeneic MSCs, and non-MSCs stem cells. |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Adverse events (person-time) | Autologous MSCs (%) | Allogeneic MSCs (%) | Non-MSCs stem cells (%) |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| N = 1028 | N = 404 | N = 1241 |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Headache | 73 (7.10) | 10 (2.48)a | 111 (8.94)b |
| Dizziness | 0 (0.00) | 8 (1.98)a | 0 (0.00)b |
| Fever | 81 (7.88) | 8 (1.98)a | 109 (8.78)b |
| Nausea | 10 (0.97) | 2 (0.50) | 18 (1.45) |
| Pain at puncture site | 75 (7.30) | 7 (1.73)a | 26 (2.10)a |
| Neck pain | 2 (0.19) | 1 (0.25) | 0 (0.00) |

aP < 0.05 compared with autologous MSCs. bP < 0.05 compared with allogeneic MSCs.
dizziness was slightly higher in our study than in those exploring autologous MSCs and non-MSCs stem cells, while the proportion with pain at the puncture site was slightly higher than those found in allogeneic MSCs trials. In those studies, other adverse events were reported; in particular, two serious adverse events were reported, and both were seizures. In the first article describing the occurrence of seizure [24], the author proposed that the event was attributable to the secondary lysis of high numbers of injected cells, especially because 50% of the cells were administered through a cisternal puncture. We suggest that the seizure might have been associated with the procedure used to prepare the cells, which was not described in detail. In the second article describing the occurrence of seizure [46], the authors stated that the patient had a medical history of seizure and experienced a reactivation of the prior epileptic seizures after the therapy. We suggest that the use of specific types of progenitor cells in children might stimulate epilepsy. We also summarized other safety indicators, such as examinations of CSF or haematological indicators and MRI results, and we found that there was no significant difference between the results reported in the literature and in our study.

We identified issues associated with collecting data on adverse events in previous clinical trials. First, some of the studies focused primarily on functional outcomes and did not record adverse events based on careful observation, and in some cases, the studies even ignored adverse events. Second, some studies did not record the data in an appropriate manner, with statistics in person-time being more suitable. Third, some of the trials observed adverse events within a short time period, which may have resulted in data loss. Fourth, when recording data in children and unconscious patients, some of the patients will not be able to fully express (or express at all) their feelings of discomfort. All these factors might result in inaccurate or incomplete data.

Certain deficiencies were observed in our study. First, because intrathecal injection is an invasive method which means that it is unethical for patients or healthy people to be intrathecally injected with placebo (such as normal saline), we did not set up a control group. It may be therefore difficult to exclude the placebo effect. Second, fewer cases were included; thus, bias might have been introduced in the trial. Lastly, the follow-up period was inconsistent and varied from 6 to 42 months. During the follow-up period, some patients did not undergo a review of MRI examinations, and it was therefore difficult to compare changes that occurred between timepoints before and after treatment.

After accessing the safety and feasibility of MSCs, we will further evaluate the effectiveness of intrathecal injection of MSCs in the treatment of specific neurological diseases. There have been many clinical trials and reviews to analyse the success rate of MSCs treatment. For applications of MSCs therapy, standardization procedures for MSCs production is the most critical step, rather than focusing on the clonality of MSCs [49]. Donor heterogeneity, ex vivo expansion, immunogenicity, and cryopreservation are important issues that must be addressed [50]. Evaluating the percentage of stem/progenitor cells before delivering MSCs to the patients is essential [51], while the presence of senescent cells in a batch of MSCs may also be taken into account [52]. More studies have shown that MSCs immunomodulatory activity has a lot to do with Indoleamine 2,3-Dioxygenase (IDO) production following treatment of MSCs with interferon gamma (IFN-γ) [53]. The consideration of these factors has far-reaching significance for the analysis of the effectiveness of repeated intrathecal allogeneic BM-MSCs in patients with neurological diseases.

5. Conclusions

In summary, the results of our study and the comparison of our data with the data presented in previous studies showed that intrathecal injection of allogeneic BM-MSCs for the treatment of neurological diseases is safe and feasible and has good clinical application prospects.

Data Availability

All data are provided in full in the Results and the necessary details can be provided by the corresponding author under request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Acknowledgments

The study was supported by funding from the Science and Technology Program of Guangdong Province, China (no. 2015A020212018).

Supplementary Materials

The procedures for preparing allogeneic BM-MSCs.

(Supplementary Materials)

References

[1] E. E. Benarroch, "The clinical approach to autonomic failure in neurological disorders," Nature Reviews Neurology, vol. 10, no. 7, pp. 396–407, 2014.

[2] A. Polymeri, W. V. Giannobile, and D. Kaigler, "Bone marrow stromal stem cells in tissue engineering and regenerative medicine," Hormone and Metabolic Research, vol. 48, no. 11, pp. 700–713, 2016.

[3] T. Squillaro, G. Peluso, and U. Galderisi, "Clinical trials with mesenchymal stem cells: an update," Cell Transplantation, vol. 25, no. 5, pp. 829–848, 2016.

[4] A. Lucia Maria Ferri, A. Bersano, D. Lisini, G. Boncoraglio, S. Frigerio, and E. Parati, "Mesenchymal stem cells for ischemic stroke: progress and possibilities," Current Medicinal Chemistry, vol. 23, no. 16, pp. 1598–1608, 2016.

[5] M. Dominici, K. Le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement," Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006.

[6] J. Zhang, X. Huang, H. Wang et al., "The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-
O. Lindvall and Z. Kokaia, “Intrathecal injection of allogenic bone marrow-derived mesenchymal stromal cells in treatment of patients with severe ischemic stroke: study protocol for a randomized controlled observer-blinded trial,” *Translational Stroke Research*, vol. 10, no. 2, pp. 170–177, 2019.

D. Karussis, P. Petrou, and I. Kassis, “Clinical experience with stem cells and other cell therapies in neurological diseases,” *Journal of the Neurological Sciences*, vol. 324, no. 1-2, pp. 1–9, 2013.

P. L. Martinez-Morales, A. Revilla, I. Ocaña et al., “Regenerative cellular therapies for neurologic disorders,” *Brain Research*, vol. 1638, Part A, pp. 88–96, 2016.

O. Lindvall and Z. Kokaia, “Stem cells in human neurodegenerative disorders—time for clinical translation?,” *Journal of Clinical Investigation*, vol. 120, no. 1, pp. 29–40, 2010.

GBD 2015 Neurological Disorders Collaborator Group, “Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015,” *The Lancet Neurology*, vol. 16, no. 11, pp. 877–897, 2017.

R. L. F. Cecil, L. Goldman, and A. I. Schafer, *Goldman’s Cecil Medicine, Expert Consult Premium Edition—Enhanced Online Features and Print, Single Volume, 24th Edition*, Elsevier /Saunders, 2012.

Y. Wu, M. Ren, R. Yang et al., “Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+ Th1/Treg cell subset imbalance in ankylosing spondylitis,” *Arthritis Research and Therapy*, vol. 13, no. 1, p. R29, 2011.

P. Wang, Y. Li, L. Huang et al., “Effects and safety of allogenic mesenchymal stem cell intravenous infusion in active ankylosing spondylitis patients who failed NSAIDs: a 20-week clinical trial,” *Cell Transplantation*, vol. 23, no. 10, pp. 1293–1303, 2014.

D. Karussis, C. Karageorgiou, A. Vaknin-Dembinsky et al., “Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis,” *Archives of Neurology*, vol. 67, no. 10, pp. 1187–1194, 2010.

H. Y. Kim, H. Kim, K. W. Oh et al., “Biological markers of mesenchymal stromal cell as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator-initiated trial and in vivo study,” *Stem Cells*, vol. 32, no. 10, pp. 2724–2731, 2014.

K. W. Oh, C. Moon, H. Y. Kim et al., “Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis,” *Stem Cells Translational Medicine*, vol. 4, no. 6, pp. 590–597, 2015.

Y. N. Rushkevich, S. M. Kosmacheva, G. V. Zabrodets et al., “The use of autologous mesenchymal stem cells for cell therapy of patients with amyotrophic lateral sclerosis in Belarus,” *Bulletin of Experimental Biology and Medicine*, vol. 159, no. 4, pp. 576–581, 2015.

P. Petrou, Y. Gothelf, Z. Argov et al., “Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials,” *JAMA Neurology*, vol. 73, no. 3, pp. 337–344, 2016.

N. P. Staff, N. N. Madigan, J. Morris et al., “Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS,” *Neurology*, vol. 87, no. 21, pp. 2230–2234, 2016.

E. Sykova, P. Rychmach, I. Drahorádová et al., “Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: results of phase I/IIa clinical trial,” *Cell Transplantation*, vol. 26, no. 4, pp. 647–658, 2017.

M. Mohyeddin Bonab, S. Yazdanbakhsh, J. Lotfi et al., “Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study,” *Iranian Journal of Immunology*, vol. 4, no. 1, pp. 50–57, 2007.

B. Yamout, R. Hourani, H. Salti et al., “Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study,” *Journal of Neuroimmunology*, vol. 227, no. 1-2, pp. 185–189, 2010.

A. M. A. Hammad, A. Marino, and S. Farhan, “Clinical outcome of 50 progressive multiple sclerosis patients treated with cellular therapy in Iraq,” *International Journal of Stem Cells*, vol. 4, no. 2, pp. 113–115, 2011.

M. Mohyeddin Bonab, M. Ali Sahraian, A. Aghaei et al., “Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study,” *Current Stem Cell Research & Therapy*, vol. 7, no. 6, pp. 407–414, 2012.

R. Pal, N. K. Venkataramana, A. Bansal et al., “Ex vivo expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: a pilot clinical study,” *Cytotherapy*, vol. 11, no. 7, pp. 897–911, 2009.

N. A. Kishk, H. Gabr, S. Hamdy et al., “Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury,” *Neurorehabilitation and Neural Repair*, vol. 24, no. 8, pp. 702–708, 2010.

S. Karamouzian, S. N. Nematollahi-Mahani, N. Nakhaei, and H. Eskandary, “Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients,” *Clinical Neurology and Neurosurgery*, vol. 114, no. 7, pp. 935–939, 2012.

J. W. Hur, T. H. Cho, D. H. Park, J. B. Lee, J. Y. Park, and Y. G. Chung, “Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: a human trial,” *The Journal of Spinal Cord Medicine*, vol. 39, no. 6, pp. 655–664, 2016.

H. S. Satti, A. Waheed, P. Ahmed et al., “Autologous mesenchymal stromal cell transplantation for spinal cord injury: a phase I pilot study,” *Cytotherapy*, vol. 18, no. 4, pp. 518–522, 2016.

J. Vaquero, M. Zurita, M. A. Rico et al., “Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury,” *Cytotherapy*, vol. 19, no. 3, pp. 349–359, 2017.

C. Tian, X. Wang, X. Wang et al., “Autologous bone marrow mesenchymal stem cell therapy in the subacute stage of traumatic brain injury by lumbar puncture,” *Experimental and Clinical Transplantation*, vol. 11, no. 2, pp. 176–181, 2013.

F. Hlebokazov, T. Dakukina, S. Ihnatsenko et al., “Treatment of refractory epilepsy patients with autologous mesenchymal stem cells reduces seizure frequency: an open label study,” *Advances in Medical Sciences*, vol. 62, no. 2, pp. 273–279, 2017.
[35] X. Liu, X. Fu, G. Dai et al., "Comparative analysis of curative effect of bone marrow mesenchymal stem cell and bone marrow mononuclear cell transplantation for spastic cerebral palsy,” Journal of Translational Medicine, vol. 15, no. 1, p. 48, 2017.

[36] J. L. Jin, Z. Liu, Z. J. Lu et al., “Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spino-cerebellar ataxia,” Current Neurovascular Research, vol. 10, no. 1, pp. 11–20, 2013.

[37] J. Liu, D. Han, Z. Wang et al., "Comparative analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells," Cytotherapy, vol. 15, no. 2, pp. 185–191, 2013.

[38] Y. T. Lv, Y. Zhang, M. Liu et al., “Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism,” Journal of Translational Medicine, vol. 11, no. 1, p. 196, 2013.

[39] S. Wang, H. Cheng, G. Dai et al., “Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury,” Brain Research, vol. 1532, pp. 76–84, 2013.

[40] F. Callera and R. X. do Nascimento, "Delivery of autologous bone marrow precursor cells into the spinal cord via lumbar puncture technique in patients with spinal cord injury: a preliminary safety study," Experimental Hematology, vol. 34, no. 2, pp. 130-131, 2006.

[41] A. A. Kumar, S. R. Kumar, R. Narayanan, K. Arul, and M. Baskaran, “Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: a phase I/II clinical safety and primary efficacy data,” Experimental and Clinical Transplantation, vol. 7, no. 4, pp. 241–248, 2009.

[42] F. Saito, T. Nakatani, M. Iwase et al., “Administration of cultured autologous bone marrow stromal cells into cerebrospinal fluid in spinal injury patients: a pilot study,” Restorative Neurology and Neuroscience, vol. 30, no. 2, pp. 127–136, 2012.

[43] A. Sharma, N. Gokulchandran, G. Chopra et al., “Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life,” Cell Transplantation, vol. 21, 1_Supplement, pp. 79–90, 2012.

[44] C. Mancias-Guerra, A. R. Marroquin-Escamilla, O. Gonzalez-Llano et al., “Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial,” Cytotherapy, vol. 16, no. 6, pp. 810–820, 2014.

[45] W. Z. Yang, Y. Zhang, F. Wu et al., “Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions,” Journal of Translational Medicine, vol. 8, no. 1, p. 75, 2010.

[46] A. Zali, L. Arab, F. Ashrafi et al., “Intrathecal injection of CD133-positive enriched bone marrow progenitor cells in children with cerebral palsy: feasibility and safety,” Cytotherapy, vol. 17, no. 2, pp. 232–241, 2015.

[47] H. Bansal, P. Verma, A. Agrawal, J. Leon, I. B. Sundell, and P. S. Koka, “A short study report on bone marrow aspirate concentrate cell therapy in ten South Asian Indian patients with autism,” Journal of Stem Cells, vol. 11, no. 1, pp. 25–36, 2016.

[48] H. Bansal, P. Verma, A. Agrawal, J. Leon, I. B. Sundell, and P. S. Koka, "Autologous bone marrow-derived stem cells in spinal cord injury," Journal of Stem Cells, vol. 11, no. 1, pp. 51–61, 2016.

[49] U. Galderisi and A. Giordano, “The gap between the physiological and therapeutic roles of mesenchymal stem cells,” Medicinal Research Reviews, vol. 34, no. 5, pp. 1100–1126, 2014.

[50] J. Galipeau, “The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?,” Cytotherapy, vol. 15, no. 1, pp. 2–8, 2013.

[51] R. Cuthbert, S. A. Boxall, H. B. Tan, P. V. Giannoudis, D. McGonagle, and E. Jones, "Single-platform quality control assay to quantify multipotential stromal cells in bone marrow aspirates prior to bulk manufacture or direct therapeutic use,” Cytotherapy, vol. 14, no. 4, pp. 431–440, 2012.

[52] S. Capasso, N. Alessio, T. Squillaro et al., "Changes in autophagy, proteasome activity and metabolism to determine a specific signature for acute and chronic senescent mesenchymal stromal cells,” Oncotarget, vol. 6, no. 37, pp. 39457–39468, 2015.

[53] M. Krampera, J. Galipeau, Y. Shi, K. Tarte, and L. Sensebe, “Immunological characterization of multipotent mesenchymal stromal cells—the International Society for Cellular Therapy (ISCT) working proposal,” Cytotherapy, vol. 15, no. 9, pp. 1054–1061, 2013.